These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 34433763)

  • 1. Plasma renin and aldosterone concentrations related to endovascular ultrasound renal denervation in the RADIANCE-HTN SOLO trial.
    Fisher NDL; Kirtane AJ; Daemen J; Rader F; Lobo MD; Saxena M; Abraham J; Schmieder RE; Sharp ASP; Gosse P; Claude L; Song Y; Azizi M;
    J Hypertens; 2022 Feb; 40(2):221-228. PubMed ID: 34433763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endovascular Ultrasound Renal Denervation to Treat Hypertension: The RADIANCE II Randomized Clinical Trial.
    Azizi M; Saxena M; Wang Y; Jenkins JS; Devireddy C; Rader F; Fisher NDL; Schmieder RE; Mahfoud F; Lindsey J; Sanghvi K; Todoran TM; Pacella J; Flack J; Daemen J; Sharp ASP; Lurz P; Bloch MJ; Weber MA; Lobo MD; Basile J; Claude L; Reeve-Stoffer H; McClure CK; Kirtane AJ;
    JAMA; 2023 Feb; 329(8):651-661. PubMed ID: 36853250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Renal Denervation vs Sham in Resistant Hypertension After Medication Escalation: Prespecified Analysis at 6 Months of the RADIANCE-HTN TRIO Randomized Clinical Trial.
    Azizi M; Mahfoud F; Weber MA; Sharp ASP; Schmieder RE; Lurz P; Lobo MD; Fisher NDL; Daemen J; Bloch MJ; Basile J; Sanghvi K; Saxena M; Gosse P; Jenkins JS; Levy T; Persu A; Kably B; Claude L; Reeve-Stoffer H; McClure C; Kirtane AJ;
    JAMA Cardiol; 2022 Dec; 7(12):1244-1252. PubMed ID: 36350593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-Level Pooled Analysis of Ultrasound Renal Denervation in the Sham-Controlled RADIANCE II, RADIANCE-HTN SOLO, and RADIANCE-HTN TRIO Trials.
    Kirtane AJ; Sharp ASP; Mahfoud F; Fisher NDL; Schmieder RE; Daemen J; Lobo MD; Lurz P; Basile J; Bloch MJ; Weber MA; Saxena M; Wang Y; Sanghvi K; Jenkins JS; Devireddy C; Rader F; Gosse P; Sapoval M; Barman NC; Claude L; Augustin D; Thackeray L; Mullin CM; Azizi M;
    JAMA Cardiol; 2023 May; 8(5):464-473. PubMed ID: 36853627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 12-Month Results From the Unblinded Phase of the RADIANCE-HTN SOLO Trial of Ultrasound Renal Denervation.
    Azizi M; Daemen J; Lobo MD; Mahfoud F; Sharp ASP; Schmieder RE; Wang Y; Saxena M; Lurz P; Sayer J; Bloch MJ; Basile J; Weber MA; Rump LC; Levy T; Sapoval M; Sanghvi K; Rader F; Fisher NDL; Gosse P; Abraham J; Claude L; Barman NC; McClure CK; Liu Y; Kirtane AJ;
    JACC Cardiovasc Interv; 2020 Dec; 13(24):2922-2933. PubMed ID: 33357531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Six-Month Results of Treatment-Blinded Medication Titration for Hypertension Control After Randomization to Endovascular Ultrasound Renal Denervation or a Sham Procedure in the RADIANCE-HTN SOLO Trial.
    Azizi M; Schmieder RE; Mahfoud F; Weber MA; Daemen J; Lobo MD; Sharp ASP; Bloch MJ; Basile J; Wang Y; Saxena M; Lurz P; Rader F; Sayer J; Fisher NDL; Fouassier D; Barman NC; Reeve-Stoffer H; McClure C; Kirtane AJ;
    Circulation; 2019 May; 139(22):2542-2553. PubMed ID: 30880441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial.
    Azizi M; Schmieder RE; Mahfoud F; Weber MA; Daemen J; Davies J; Basile J; Kirtane AJ; Wang Y; Lobo MD; Saxena M; Feyz L; Rader F; Lurz P; Sayer J; Sapoval M; Levy T; Sanghvi K; Abraham J; Sharp ASP; Fisher NDL; Bloch MJ; Reeve-Stoffer H; Coleman L; Mullin C; Mauri L;
    Lancet; 2018 Jun; 391(10137):2335-2345. PubMed ID: 29803590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ambulatory Blood Pressure Monitoring to Predict Response to Renal Denervation: A Post Hoc Analysis of the RADIANCE-HTN SOLO Study.
    Gosse P; Cremer A; Kirtane AJ; Lobo MD; Saxena M; Daemen J; Wang Y; Stegbauer J; Weber MA; Abraham J; Kario K; Bangalore S; Claude L; Liu Y; Azizi M
    Hypertension; 2021 Feb; 77(2):529-536. PubMed ID: 33356403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in Plasma Renin Activity After Renal Artery Sympathetic Denervation.
    Mahfoud F; Townsend RR; Kandzari DE; Kario K; Schmieder RE; Tsioufis K; Pocock S; David S; Patel K; Rao A; Walton A; Bloom JE; Weber T; Suppan M; Lauder L; Cohen SA; McKenna P; Fahy M; Böhm M; Weber MA
    J Am Coll Cardiol; 2021 Jun; 77(23):2909-2919. PubMed ID: 33957242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial.
    Townsend RR; Mahfoud F; Kandzari DE; Kario K; Pocock S; Weber MA; Ewen S; Tsioufis K; Tousoulis D; Sharp ASP; Watkinson AF; Schmieder RE; Schmid A; Choi JW; East C; Walton A; Hopper I; Cohen DL; Wilensky R; Lee DP; Ma A; Devireddy CM; Lea JP; Lurz PC; Fengler K; Davies J; Chapman N; Cohen SA; DeBruin V; Fahy M; Jones DE; Rothman M; Böhm M;
    Lancet; 2017 Nov; 390(10108):2160-2170. PubMed ID: 28859944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The REDUCE HTN: REINFORCE: Randomized, Sham-Controlled Trial of Bipolar Radiofrequency Renal Denervation for the Treatment of Hypertension.
    Weber MA; Kirtane AJ; Weir MR; Radhakrishnan J; Das T; Berk M; Mendelsohn F; Bouchard A; Larrain G; Haase M; Diaz-Cartelle J; Leon MB
    JACC Cardiovasc Interv; 2020 Feb; 13(4):461-470. PubMed ID: 32081240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Durability of blood pressure reduction after ultrasound renal denervation: three-year follow-up of the treatment arm of the randomised RADIANCE-HTN SOLO trial.
    Rader F; Kirtane AJ; Wang Y; Daemen J; Lurz P; Sayer J; Saxena M; Levy T; Scicli AP; Thackeray L; Azizi M; Weber MA
    EuroIntervention; 2022 Oct; 18(8):e677-e685. PubMed ID: 35913759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial.
    Bhatt DL; Vaduganathan M; Kandzari DE; Leon MB; Rocha-Singh K; Townsend RR; Katzen BT; Oparil S; Brar S; DeBruin V; Fahy M; Bakris GL;
    Lancet; 2022 Oct; 400(10361):1405-1416. PubMed ID: 36130612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in blood pressure after crossover to ultrasound renal denervation in patients initially treated with sham in the RADIANCE-HTN SOLO trial.
    Mahfoud F; Bloch MJ; Azizi M; Wang Y; Schmieder RE; Lobo MD; Sharp ASP; Daemen J; Basile J; Weber MA; Scicli AP; McClure CK; Kirtane AJ
    EuroIntervention; 2021 Dec; 17(12):e1024-e1032. PubMed ID: 34236037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Antihypertensive Drugs of Different Classes After Renal Denervation in Spontaneously Hypertensive Rats.
    Hohl M; Lauder L; Sevimli Ö; Tokcan M; Wagmann L; Götzinger F; Schneider C; Hübner U; Lehnert U; Meyer MR; Böhm M; Mahfoud F
    Hypertension; 2023 Jun; 80(6):e90-e100. PubMed ID: 36999443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-Level Pooled Analysis of Endovascular Ultrasound Renal Denervation or a Sham Procedure 6 Months After Medication Escalation: The RADIANCE Clinical Trial Program.
    Azizi M; Sharp ASP; Fisher NDL; Weber MA; Lobo MD; Daemen J; Lurz P; Mahfoud F; Schmieder RE; Basile J; Bloch MJ; Saxena M; Wang Y; Sanghvi K; Jenkins JS; Devireddy C; Rader F; Gosse P; Claude L; Augustin DA; McClure CK; Kirtane AJ;
    Circulation; 2024 Mar; 149(10):747-759. PubMed ID: 37883784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial.
    Azizi M; Sanghvi K; Saxena M; Gosse P; Reilly JP; Levy T; Rump LC; Persu A; Basile J; Bloch MJ; Daemen J; Lobo MD; Mahfoud F; Schmieder RE; Sharp ASP; Weber MA; Sapoval M; Fong P; Pathak A; Lantelme P; Hsi D; Bangalore S; Witkowski A; Weil J; Kably B; Barman NC; Reeve-Stoffer H; Coleman L; McClure CK; Kirtane AJ;
    Lancet; 2021 Jun; 397(10293):2476-2486. PubMed ID: 34010611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multinational clinical approach to assessing the effectiveness of catheter-based ultrasound renal denervation: The RADIANCE-HTN and REQUIRE clinical study designs.
    Mauri L; Kario K; Basile J; Daemen J; Davies J; Kirtane AJ; Mahfoud F; Schmieder RE; Weber M; Nanto S; Azizi M
    Am Heart J; 2018 Jan; 195():115-129. PubMed ID: 29224639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial.
    Mahfoud F; Kandzari DE; Kario K; Townsend RR; Weber MA; Schmieder RE; Tsioufis K; Pocock S; Dimitriadis K; Choi JW; East C; D'Souza R; Sharp ASP; Ewen S; Walton A; Hopper I; Brar S; McKenna P; Fahy M; Böhm M
    Lancet; 2022 Apr; 399(10333):1401-1410. PubMed ID: 35390320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood pressure and neurohormonal responses to renal nerve ablation in treatment-resistant hypertension.
    Ezzahti M; Moelker A; Friesema EC; van der Linde NA; Krestin GP; van den Meiracker AH
    J Hypertens; 2014 Jan; 32(1):135-41. PubMed ID: 24131897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.